Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clearside Biomedical excels in 2022, eyes trial milestones and partnerships

Clearside Biomedical's strong performance in 2022, supported by key achievements and financial stability, positions the company well for future growth and innovation.
While facing challenges such as trial design adjustments and addressing analyst inquiries, Clearside's strategic partnerships and upcoming trials offer significant opportunities for expansion and market advancement.

Clearside Biomedical reports positive OASIS trial results and financial stability

Clearside Biomedical's Q1 2023 performance reflects advancements in CLS-AX development and financial stability
Challenges include addressing analyst inquiries and potential resistance to extended duration treatments
Opportunities lie in leading treatment innovation and expanding investor engagement through conferences and filings

Clearside Biomedical advances in wet AMD treatment with innovative approach

Clearside Biomedical's Q2 2023 earnings call highlighted strong progress in their lead program, financial stability, and innovative delivery technology, positioning them well in the market.
The company's differentiated mechanistic approach and potential for combination therapies offer competitive advantages and opportunities for market expansion.
While facing challenges in proving efficacy, financial sustainability, and market adoption, Clearside's strategic collaborations and diverse portfolio present avenues for growth and success.

Clearside Biomedical advances trials and partnerships, eyes growth opportunities

Clearside Biomedical's Q3 2023 Earnings Call highlighted progress in trials, partnerships, and cash position. Challenges include trial enrollment and design considerations, while opportunities exist in value creation and milestone achievements by partners.

Clearside Biomedical reports positive 2023 progress and financial stability

Clearside Biomedical made significant progress in 2023, with a focus on advancing key clinical programs and collaborations.
Financially, the company is well-positioned with sufficient resources to support operations until the third quarter of 2025.
Challenges lie in successfully completing ongoing trials and maintaining competitiveness in the evolving landscape of vision treatments.
Opportunities abound in innovative drug delivery approaches, therapeutic advancements, and strategic collaborations for Clearside.

Clearside Biomedical reports stable finances and bullish outlook on CLS-AX

Clearside Biomedical's Q1 2024 earnings call highlighted a stable financial position, key leadership additions, and the promising potential of CLS-AX in treating retinal diseases. Analyst inquiries underscored areas of interest and scrutiny, pointing to the company's need for continued strategic development and adherence to regulatory standards.

Clearside Biomedical reports positive trial results and strategic leadership changes

Clearside Biomedical's Q3 2024 earnings call highlighted promising trial results, financial stability, and strategic leadership changes.
The company's strengths lie in its innovative suprachoroidal platform, strong partnerships, and positive trial outcomes for wet AMD treatment.
While facing challenges in trial design and funding, Clearside Biomedical has opportunities in geographic atrophy treatment and flexible dosing strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Pfizer veteran brings global R&D expertise to Board of Directors - - Pfizer veteran brings global R&D expertise to Board of Directors -

Clearside Biomedical Appoints Nancy J. Hutson, Ph.D.

ALPHARETTA, Ga., April  09, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation of a Scientific Advisory Board comprised of world-renowned retinal physicians to advise on the Company’s research and development programs. 

Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2019 Results - Earnings Call Transcript

ALPHARETTA, Ga., March  11, 2020  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective March 1, 2020.

Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

– Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia –  – Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on Product Sales –  – Increasing Global Awareness of Innovative Suprachoroidal Injection Platform –

Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

Presentations to Focus on Novel Suprachoroidal Delivery of CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration Presentations to Focus on Novel Suprachoroidal Delivery of CLS-AX (axitinib injectable suspension) as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration

Clearside Biomedical Announces Presentations to be Given at Angiogenesis and Macula Society Conferences

As of late, it has definitely been a great time to be an investor in Clearside Biomedical.

Will Clearside Biomedical Continue to Surge Higher?

Investors need to pay close attention to Clearside Biomedical (CLSD) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Clearside Biomedical (CLSD) Stock?

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q3 2019 Results - Earnings Call Transcript

REGENXBIO

ALPHARETTA, Ga., Oct.  30, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that REGENXBIO Inc. (Nasdaq: RGNX) has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector™ for the delivery of adeno-associated virus (AAV)-based therapeutics, including but not limited to RGX-314 delivery to the suprachoroidal space to potentially treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other conditions for which chronic anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care.

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients XIPERE™ presentations continue to demonstrate the potential value to treat uveitis patients

Clearside Biomedical Suprachoroidal Injection Platform Featured in Multiple Presentations at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting

ALPHARETTA, Ga., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous presentations were given at three scientific congresses in Europe over the past two weeks.

Clearside Biomedical Featured at Multiple European Scientific Retinal Congresses

Clearside Biomedical Inc (NASDAQ: CLSD) shares — which came under intense selling pressure in late August after the company hinted at a possible FDA rejection of the NDA for its macular edema drug — got a reprieve Wednesday.

Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbio

ALPHARETTA, Ga., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., Chief Executive Officer, will present a company overview at the Janney Montgomery Scott Healthcare Conference in New York, NY on Tuesday, September 10, 2019 at 8:15 a.m. ET.

Clearside Biomedical to Present at the Janney Montgomery Scott Healthcare Conference

Clearside Biomedical Inc (NASDAQ: CLSD) shares entered penny stock territory Thursday after the company issued an update on what transpired at a meeting with the FDA regarding the new drug application for Xipere.

Clearside Stock Plummets After Company Hints At Complete Response Letter For Macular Edema Drug

ALPHARETTA, Ga., Aug.  22, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update regarding the Company’s 505(b)(2) New Drug Application (NDA) for XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) with the U.S. Food and Drug Administration (FDA).

Clearside Biomedical Provides New Drug Application Update for XIPEREᵀᴹ (triamcinolone acetonide suprachoroidal injectable suspension)

Clearside Biomedical's (CLSD) CEO George Lasezkay on Q2 2019 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 59.46% and -10.00%, respectively, for the quarter ended June 2019.

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Misses Revenue Estimates

Clearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q1 2019 Results - Earnings Call Transcript

News for Clearside Biomedical Stock (CLSD)